Long response and long responders in melanoma immunology
5 Nov 2015
Long response and long responders in melanoma immunology
The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma
Benefit and risk analysis from the phase III OPTiM trial
Progress in targeted therapy of melanoma
Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study
Melanoma prevention: Do we need sunlight for vitamin D?
Why is screening for melanoma important?
Management of acute metastatic melanoma
How should we handle talimogene laherparepvec (T-VEC)?
New challenges in drug combination and strategies
Editor's choice for October 2015
Targeting N-RAS mutated tumours